Screening for Cancer-Treatment-Related Bone Loss: Clinical Implications and Evidence-Based Strategies

Abstract

Cancer-treatment-related bone loss (CTBL) is a significant and underrecognized complication among cancer survivors, impacting morbidity and overall quality of life. This review synthesizes current evidence on the epidemiology, pathophysiology, risk assessment, clinical features, diagnostic strategies, management, and recent advances in the screening and prevention of CTBL. Guideline recommendations are critically appraised to provide an integrated framework for clinicians managing patients at risk of skeletal complications following oncological therapies.

Introduction

Advancements in cancer therapeutics have markedly improved survival rates, leading to an increasing population of cancer survivors who are at heightened risk for long-term treatment-related comorbidities. Among these, bone loss induced by chemotherapy, endocrine therapy, and targeted agents is a clinically relevant problem, particularly in breast, prostate, and hematological malignancies. Early identification and management of CTBL are essential to minimizing fracture risk, preserving functional independence, and optimizing survivorship outcomes. This review aims to provide a comprehensive, evidence-based overview of screening and management strategies for CTBL, with a focus on recent research and guideline-directed care.

Epidemiology / Disease Burden

The incidence of CTBL varies depending on cancer type, therapeutic regimen, and patient-related factors. In breast cancer, aromatase inhibitors accelerate bone turnover, with up to 20% of postmenopausal women developing osteoporosis within five years of therapy initiation. Prostate cancer patients exposed to androgen deprivation therapy (ADT) face a 3- to 4-fold increased risk of fractures. Hematological malignancy survivors, especially those undergoing hematopoietic stem cell transplantation, exhibit rapid bone mineral density (BMD) loss post-treatment. CTBL substantially contributes to morbidity, with fractures linked to increased hospitalization, healthcare utilization, and mortality. The growing survivor population underscores the need for proactive bone health assessment in clinical oncology.

Pathophysiology

The pathogenesis of CTBL is multifactorial, involving direct and indirect effects of cancer therapies. Chemotherapeutic agents, corticosteroids, and radiotherapy disrupt osteoblast function, enhance osteoclast-mediated bone resorption, and impair calcium and vitamin D metabolism. Endocrine therapies, such as aromatase inhibitors and ADT, precipitate hypogonadism, leading to decreased estrogen or testosterone, both critical for skeletal homeostasis. Emerging targeted therapies may also exert off-target effects on bone remodeling pathways. The resultant net bone loss is characterized by cortical thinning, trabecular perforation, and microarchitectural deterioration, predisposing patients to fragility fractures.

Risk Factors

Several risk factors modulate susceptibility to CTBL, including baseline low BMD, advanced age, female sex, low body mass index, smoking, excessive alcohol intake, physical inactivity, and family history of osteoporosis. Cancer-specific factors, such as type and duration of therapy, cumulative corticosteroid exposure, and coexisting nutritional deficiencies, further compound risk. Patients with hematological malignancies, those receiving high-dose chemotherapy or total body irradiation, and postmenopausal women are especially vulnerable. Comprehensive risk stratification is pivotal in guiding individualized screening and preventive interventions.

Clinical Features

CTBL is often clinically silent until a fracture occurs. Vertebral compression fractures may manifest as acute back pain, height loss, or kyphosis, while nonvertebral fractures of the hip or wrist can result in significant morbidity, loss of independence, and increased mortality. Subtle symptoms such as chronic musculoskeletal pain or reduced mobility warrant a high index of suspicion, particularly in at-risk populations. Awareness of the insidious nature of CTBL is critical to prompt identification and intervention.

Diagnosis

Dual-energy X-ray absorptiometry (DXA) remains the gold standard for quantifying BMD and diagnosing osteoporosis in cancer survivors. Recent guidelines advocate baseline DXA screening at cancer diagnosis or prior to initiating high-risk therapies, with follow-up scans at 12-24 month intervals or as clinically indicated. Vertebral fracture assessment (VFA) by DXA or lateral spine radiographs enhances detection of asymptomatic vertebral fractures. Laboratory evaluation should include serum calcium, 25(OH) vitamin D, thyroid function, and, when indicated, markers of bone turnover. Risk assessment tools such as FRAX, adapted for oncology populations, aid in estimating 10-year fracture probability and inform management decisions.

Treatment & Management

Management of CTBL encompasses both lifestyle modification and pharmacologic interventions. Weight-bearing exercise, smoking cessation, moderation of alcohol intake, and optimization of dietary calcium and vitamin D are foundational. Pharmacotherapy is indicated for patients with osteoporosis, prior fragility fracture, or high fracture risk. Bisphosphonates, such as zoledronic acid and alendronate, are first-line agents, with evidence supporting fracture reduction in cancer patients. Denosumab, a monoclonal antibody targeting RANKL, is increasingly utilized, particularly in those intolerant to bisphosphonates or with renal impairment. Hormone replacement may be considered in select hypogonadal patients, taking oncological contraindications into account. Adherence to therapy and monitoring for adverse effects, such as osteonecrosis of the jaw or hypocalcemia, are essential to optimizing outcomes.

Recent Advances / Emerging Therapies

Recent advances include the development of bone-targeted agents with novel mechanisms and improved safety profiles. Selective estrogen receptor modulators (SERMs) and parathyroid hormone analogs are under investigation for CTBL. Molecular therapies targeting the Wnt signaling pathway and sclerostin are emerging as promising approaches for enhancing bone formation. Advances in imaging, such as high-resolution peripheral quantitative computed tomography (HR-pQCT), allow detailed assessment of bone microarchitecture and may improve fracture risk stratification. Ongoing clinical trials are evaluating combination therapies and personalized approaches based on genetic and molecular profiling.

Guideline Recommendations

Major oncology and bone health societies, including ASCO, ESMO, and NCCN, recommend baseline and periodic BMD assessment for patients initiating therapies known to impact bone health. Calcium (1,000–1,200 mg/day) and vitamin D (800–1,000 IU/day) supplementation are universally advised. Pharmacologic therapy should be initiated for patients with osteoporosis, high fracture risk, or documented fragility fractures. Multidisciplinary collaboration between oncologists, endocrinologists, and primary care is emphasized to ensure comprehensive bone health management throughout the cancer care continuum.

Conclusion

Cancer-treatment-related bone loss is a prevalent and impactful complication in cancer survivorship, necessitating proactive screening and intervention. Evidence-based strategies, encompassing risk assessment, timely diagnosis, lifestyle modification, and targeted pharmacotherapy, are critical to mitigating fracture risk and enhancing quality of life. Ongoing research and guideline evolution will further refine screening and management paradigms, underscoring the importance of continued vigilance and multidisciplinary engagement in the care of oncology patients.